Cargando…

Minimal Residual Disease in Acute Lymphoblastic Leukemia: Current Practice and Future Directions

SIMPLE SUMMARY: Acute lymphoblastic leukemia minimal residual disease (MRD) refers to the presence of residual leukemia cells following the achievement of complete remission, but below the limit of detection using conventional morphologic assessment. Up to two thirds of children may have MRD detecta...

Descripción completa

Detalles Bibliográficos
Autores principales:	Contreras Yametti, Gloria Paz, Ostrow, Talia H., Jasinski, Sylwia, Raetz, Elizabeth A., Carroll, William L., Evensen, Nikki A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8069391/ https://www.ncbi.nlm.nih.gov/pubmed/33924381 http://dx.doi.org/10.3390/cancers13081847

Ejemplares similares

Flow cytometric assessment of leukemia-associated monocytes in childhood B-cell acute lymphoblastic leukemia outcome
por: Contreras Yametti, Gloria P., et al.
Publicado: (2023)

Minimal Residual Disease Detection in Acute Lymphoblastic Leukemia
por: Kruse, Aaron, et al.
Publicado: (2020)

Minimal Residual Disease in Acute Lymphoblastic Leukemia: Technical and Clinical Advances
por: Della Starza, Irene, et al.
Publicado: (2019)

Minimal Residual Disease in Adult Acute Lymphoblastic Leukemia: Egyptian Experience
por: Ibrahim, Rasha Ibrahim, et al.
Publicado: (2022)

Current Strategies for the Detection of Minimal Residual Disease in Childhood Acute Lymphoblastic Leukemia
por: Rocha, Juliana Maria Camargos, et al.
Publicado: (2016)

Sources of error in measurement of minimal residual disease in childhood acute lymphoblastic leukemia
por: Latham, Sue, et al.
Publicado: (2017)

Optimizing Molecular Minimal Residual Disease Analysis in Adult Acute Lymphoblastic Leukemia
por: Della Starza, Irene, et al.
Publicado: (2023)

Validation of Minimal Residual Disease as Surrogate Endpoint for Event-Free Survival in Childhood Acute Lymphoblastic Leukemia
por: Galimberti, Stefania, et al.
Publicado: (2018)

The utility of multiparametric flow cytometry for the detection of minimal residual disease in acute lymphoblastic leukemia
por: Cunha, Fernanda Gonçalves Pereira, et al.
Publicado: (2012)

Minimal residual disease in acute lymphoblastic leukemia: technical aspects and implications for clinical interpretation
por: Kim, In-Suk
Publicado: (2020)

Circulating microRNAs as minimal residual disease biomarkers in childhood acute lymphoblastic leukemia
por: Rzepiel, Andrea, et al.
Publicado: (2019)

How do mTOR inhibitors fit in the landscape of treatment for relapsed acute lymphoblastic leukemia?
por: Pinchinat, Ashley, et al.
Publicado: (2022)

Transcriptome Analysis of Minimal Residual Disease in Subtypes of Pediatric B Cell Acute Lymphoblastic Leukemia
por: Sitthi-amorn, Jitsuda, et al.
Publicado: (2015)

Proposal for the standardization of flow cytometry protocols to detect minimal residual disease in acute lymphoblastic leukemia
por: Ikoma, Maura Rosane Valério, et al.
Publicado: (2015)

Genotype-Specific Minimal Residual Disease Interpretation Improves Stratification in Pediatric Acute Lymphoblastic Leukemia
por: O’Connor, David, et al.
Publicado: (2018)

Testing for minimal residual disease in adults with acute lymphoblastic leukemia in Europe: a clinician survey
por: Pigneux, Arnaud, et al.
Publicado: (2018)

Minimal residual disease in childhood B Lymphoblastic Leukemia and its correlation with other risk factors
por: Meraj, Fatima, et al.
Publicado: (2020)

Minimal residual disease detection in Tunisian B-acute lymphoblastic leukemia based on immunoglobulin gene rearrangements
por: Besbes, S., et al.
Publicado: (2017)

TFDP3 confers chemoresistance in minimal residual disease within childhood T-cell acute lymphoblastic leukemia
por: Chu, Ming, et al.
Publicado: (2016)

Clinical Significance of Minimal Residual Disease at the End of Remission Induction Therapy in Childhood Acute Lymphoblastic Leukemia
por: Jovanovska, Aleksandra, et al.
Publicado: (2019)

Rational drug combinations with CDK4/6 inhibitors in acute lymphoblastic leukemia
por: Bride, Karen L., et al.
Publicado: (2021)

Philadelphia-like acute lymphoblastic leukemia is associated with minimal residual disease persistence and poor outcome. First report of the minimal residual disease-oriented GIMEMA LAL1913
por: Chiaretti, Sabina, et al.
Publicado: (2020)

MSH6 haploinsufficiency at relapse contributes to the development of thiopurine resistance in pediatric B-lymphoblastic leukemia
por: Evensen, Nikki A., et al.
Publicado: (2018)

Prognostic Significance and Treatment Implications of Minimal Residual Disease Studies in Philadelphia-Negative Adult Acute Lymphoblastic Leukemia
por: Spinelli, Orietta, et al.
Publicado: (2014)

Clinicians’ Perspectives on Cure in Adult Patients with Acute Lymphoblastic Leukemia with Minimal Residual Disease: A Delphi Study
por: Gidman, Wendy, et al.
Publicado: (2019)

P366: ARE MINIMAL RESIDUAL DISEASE MEASUREMENTS AFTER CONSOLIDATION THERAPY USEFUL IN CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA?
por: Stutterheim, Janine, et al.
Publicado: (2023)

Impact of Minimal Residual Disease, Detected by Flow Cytometry, on Outcome of Myeloablative Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia
por: Bar, Merav, et al.
Publicado: (2014)

Clinical Impact of Minimal Residual Disease in Children with Different Subtypes of Acute Lymphoblastic Leukemia Treated with Response-Adapted Therapy
por: Pui, Ching-Hon, et al.
Publicado: (2016)

NSD2 E1099K drives relapse in pediatric acute lymphoblastic leukemia by disrupting 3D chromatin organization
por: Narang, Sonali, et al.
Publicado: (2023)

Next-Generation Sequencing of Minimal Residual Disease for Predicting Relapse after Tisagenlecleucel in Children and Young Adults with Acute Lymphoblastic Leukemia
por: Pulsipher, Michael A., et al.
Publicado: (2022)

Detection of Immunoglobulin Heavy Chain Gene Clonality by Next-Generation Sequencing for Minimal Residual Disease Monitoring in B-Lymphoblastic Leukemia
por: Shin, Saeam, et al.
Publicado: (2017)

Improving the Identification of High Risk Precursor B Acute Lymphoblastic Leukemia Patients with Earlier Quantification of Minimal Residual Disease
por: Karsa, Mawar, et al.
Publicado: (2013)

Re-Emergence of Minimal Residual Disease Detected by Flow Cytometry Predicts an Adverse Outcome in Pediatric Acute Lymphoblastic Leukemia
por: Wang, Yu, et al.
Publicado: (2021)

Analytical evaluation of the clonoSEQ Assay for establishing measurable (minimal) residual disease in acute lymphoblastic leukemia, chronic lymphocytic leukemia, and multiple myeloma
por: Ching, Travers, et al.
Publicado: (2020)

Clinical Applications and Future Directions of Minimal Residual Disease Testing in Multiple Myeloma
por: Oliva, Stefania, et al.
Publicado: (2020)

Evolving therapy of adult acute lymphoblastic leukemia: state-of-the-art treatment and future directions
por: Samra, Bachar, et al.
Publicado: (2020)

Evaluation and management of measurable residual disease in acute lymphoblastic leukemia
por: Abou Dalle, Iman, et al.
Publicado: (2020)

Clinical Value of Measurable Residual Disease in Acute Lymphoblastic Leukemia
por: Hein, Kyaw, et al.
Publicado: (2022)

Comparison between qualitative and real-time polymerase chain reaction to evaluate minimal residual disease in children with acute lymphoblastic leukemia
por: Paula, Francisco Danilo Ferreira, et al.
Publicado: (2015)

Minimal Residual Disease Detection and Evolved IGH Clones Analysis in Acute B Lymphoblastic Leukemia Using IGH Deep Sequencing
por: Wu, Jinghua, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_6n5piujf3ib3bt0f0v56g39ikl